Han H - Search Results

1

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Borad MJ, et al. Among authors: han h. PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb. PLoS Genet. 2014. PMID: 24550739 Free PMC article.

2

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

3

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. Grand CL, et al. Among authors: han h. Mol Cancer Ther. 2002 Jun;1(8):565-73. Mol Cancer Ther. 2002. PMID: 12479216

4

Targeting Aurora-2 kinase in cancer.

Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Among authors: han h. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.

5

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: han h. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

6

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. Gray PJ Jr, et al. Among authors: han h. Mol Cancer Ther. 2004 May;3(5):641-6. Mol Cancer Ther. 2004. PMID: 15141022

7

PRL phosphatases as potential molecular targets in cancer.

Stephens BJ, Han H, Gokhale V, Von Hoff DD. Stephens BJ, et al. Among authors: han h. Mol Cancer Ther. 2005 Nov;4(11):1653-61. doi: 10.1158/1535-7163.MCT-05-0248. Mol Cancer Ther. 2005. PMID: 16275986 Review.

8

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD. Wang H, et al. Among authors: han h. Semin Oncol. 2006 Aug;33(4):513-20. doi: 10.1053/j.seminoncol.2006.04.013. Semin Oncol. 2006. PMID: 16890805 Review.

9

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Warner SL, et al. Among authors: han h. Mol Cancer Ther. 2006 Jul;5(7):1764-73. doi: 10.1158/1535-7163.MCT-05-0524. Mol Cancer Ther. 2006. PMID: 16891462

10

Aurora sheds light on head and neck squamous cell carcinoma.

Han H, Von Hoff DD. Han H, et al. Clin Cancer Res. 2006 Sep 1;12(17):5003-4. doi: 10.1158/1078-0432.CCR-06-1329. Clin Cancer Res. 2006. PMID: 16951211 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,952 results

Search Page

Filters